IBC wants to ensure that our members receive injectable/infusion therapy drugs in a setting that is both safe and cost-effective for their clinical condition. Since January 2012, IBC considers the most appropriate setting for commercial members to receive certain injectable and infusion therapy drugs as part of the precertification review process. Effective July 1, 2013, two additional drugs will require precertification based on setting. The following is the updated list of drugs that require precertification approval for setting: Aralast (alpha-1 proteinase inhibitor [human]) Berinert[^®] (C1 esterase inhibitor [human]) New for July 2013 Ceredase[^®] (alglucerase) Cerezyme[^®] (imiglucerase) Cinryze[^®] (C1 esterase inhibitor [human]) New for July 2013 Elelyso[^]TM[] (taliglucerase alfa) Fabrazyme[^®] (agalsidase beta) Glassia (alpha-1 proteinase inhibitor [human]) Intravenous immunoglobulin (IVIG) Kalbitor[^®] (ecallantide) Lucentis[^®] (ranibizumab) Lumizyme[^®] (alglucosidase alfa) Macugen[^®] (pegaptanib) Myozyme[^®] (alglucosidase alfa) Prolastin[^®] (alpha-1 proteinase inhibitor [human]) Prolia[^®] (denosumab) Soliris[^®] (eculizumab) Stelara[^®] (ustekinmab) Synribo[^]TM[] (omacetaxine mepesuccinate) VPRIV[^®] (velaglucerase alfa) Xolair[^®] (omalizumab) Zemaira[^®] (alpha-1 proteinase inhibitor [human]) These drugs continue to be covered by IBC for members who meet the clinical criteria outlined in our medical policy for each drug, but only when the drugs are administered in the most appropriate setting approved by IBC during the precertification review process. During this process, each member?s unique medical needs and clinical history will be considered to determine which setting is most appropriate. IBC will also review black box warnings included in the prescribing information for a drug at the time that precertification is requested. If there are circumstances that require a member to receive a drug in an outpatient facility, the provider must submit documentation to IBC that specifically addresses these circumstances when submitting a request for coverage. To review the medical policies for the drugs listed, visit our []Medical Policy website[] and type the name of the drug in the Search box.